• DOI:10.1182/blood-2008-02-140582
Corpus ID: 17555038

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

@article{Tam2008LongtermRO,
  title={Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.},
  author={C. Tam and S. O'brien and William Wierda and H. Kantarjian and S. Wen and K. Do and D. Thomas and J. Cort{\'e}s and S. Lerner and M. Keating},
  journal={Blood},
  year={2008},
  volume={112 4},
  pages={
          975-80
        }
}

C. Tam, S. O'brien, +7 authors M. Keating

Published 2008

Medicine

Blood

Early results of the fludarabine, cyclophosphamide, and rituximab (FCR) regimen in 224 patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia. In this report, we present the final results of all 300 study patients at a median follow up of 6 years. The overall response rate was 95%, with complete remission in 72%, nodular partial remission in 10%, partial remission due to cytopenia in 7%, and partial remission due to residual disease in 6%. Two patients (< 1… CONTINUE READING

View on PubMed

europepmc.org

Save to Library

Create Alert

Cite

Launch Research Feed